Evidence map›Paper›PMID 40374625›Full record

ArticleNature communications2025

Gfi1 controls the formation of effector-like CD8

Oluwagbemiga A Ojo, Hongxing Shen, Jennifer T Ingram, James A Bonner, Robert S Welner, Georges Lacaud, Allan J Zajac, Lewis Z Shi

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Preexisting TCR Clones Drive Major Pathologic Responses in Patients with HNSCC Treated with Dual Immune Checkpoint Inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Oluwagbemiga A OjoDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0002-0086-6694
Hongxing ShenDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-7400-6809
Jennifer T IngramDepartment of Microbiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
James A BonnerDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0002-8413-3788
Robert S WelnerDepartment of Hematology & Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0003-2498-9469
Georges LacaudCancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Allan J ZajacDepartment of Microbiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Lewis Z ShiDepartment of Radiation Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Lewisshi@uabmc.edu.ORCID http://orcid.org/0000-0002-5351-8730

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Resistance to T cell exhaustionR01AI156290 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZAJAC, ALLAN J · 2021 to 2025
$2.7M
T cell-intrinsic metabolic control of radiotherapyR01CA279849 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Lewis Z. Shi · 2024 to 2026
$1.2M
Overcoming Tumor-Intrinsic Therapeutic Resistance to ImmunotherapiesR21CA259721 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SHI, LEWIS ZHICHANG · 2022 to 2023
$378k
Targeting metabolic checkpoints in the tumor microenvironment to boost efficacy of anti-CTLA-4R21CA230475 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SHI, LEWIS ZHICHANG · 2019 to 2020
$355k
American Cancer Society (American Cancer Society, Inc.) 91-022-19Cancer Research Institute (CRI) CRI4342NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA279849NCI NIH HHS R21 CA230475NCI NIH HHS R21 CA259721NIAID NIH HHS R01 AI156290U.S. Department of Defense (United States Department of Defense) ME210108U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R01CA279849-01A1, 1R21CA230475-01A1, 1R21CA259721-01A1, 5R01AI156290U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 5R01AI156290V Foundation for Cancer Research (V Foundation) V2018-023
6 · The paper itself

Abstract

During chronic infection and tumor progression, CD8

Indexed as

CD8-Positive T-LymphocytesDNA-Binding ProteinsLymphocytic ChoriomeningitisNeoplasmsTranscription FactorsAnimalsChronic DiseaseLymphocytic choriomeningitis virusMiceMice, Inbred C57BLMice, KnockoutDNA-Binding ProteinsGfi1 protein, mouseTranscription Factors

Identifiers

PMID40374625
PMCPMC12081725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.